Enlaza Therapeutics

Covalent Protein Biologics | Home

Enlaza Therapeutics was founded in 2021, is headquartered in San Diego, United States, lists 51–200 employees, and has $161.0M in recorded funding across 2 rounds.

Employees
51–200
Founded
2021
Business Model
B2B
Total Funding
$161.0M
Last Round
$100.0M Series AApr 2024
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 10 investors for this company. The full record is or through the API.

About

Enlaza Therapeutics is a preclinical-stage biotech developing first-in-class covalent protein therapeutics, or 'War-Lock' biologics, to treat cancer and other serious diseases. Its proprietary platform incorporates unnatural amino acids into protein drugs to create irreversible, target-specific covalent bonds, aiming to improve efficacy and reduce off-target toxicity compared to standard biologics. The company is backed by investors including J.P. Morgan Life Sciences Private Capital, Frazier Life Sciences, Avalon Ventures, Lightspeed Venture Partners, and Samsara BioCapital, and announced a strategic collaboration with Vertex Pharmaceuticals in September 2025.

Summary

Enlaza Therapeutics is a Biotech company based in San Diego, United States, founded in 2021. It lists 51–200 employees. It has raised $161.0M in total across 2 rounds, most recently a $100.0M Series A round in Apr 2024. Investors include J.P. Morgan Asset Management, Avalon Ventures and Amgen.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AApr 2024
$100.0M

Sign up to see all 2 events

Funding: Seed through Series A. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
ParexelAcquired

One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...

Raleigh, United States10001+Biotech
Private EquityTotal funding$5.0BJun 2017
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Enlaza Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/enlaza-therapeutics"><img src="https://indexed.vc/api/badge/company/enlaza-therapeutics" alt="Enlaza Therapeutics on Indexed.vc" width="260" height="76" /></a>